Zero stage breast cancer, officially called stage 0, is a condition where abnormal cells have formed inside the milk ducts of the breast but have not spread beyond the duct walls into surrounding tissue. It accounts for roughly 20% to 25% of all newly diagnosed breast cancers in the United States. The most common form is ductal carcinoma in situ, or DCIS, and despite the word “cancer” in its name, it is considered noninvasive because the abnormal cells remain contained.
What Happens Inside the Breast
In a healthy breast, the cells lining the milk ducts grow and replace themselves in an orderly way. In DCIS, those lining cells have begun multiplying abnormally, but they stay within the duct walls. Think of it like rust forming on the inside of a pipe: the pipe itself is still intact. Because the abnormal cells haven’t broken through, they can’t reach blood vessels or lymph nodes, which means they can’t spread to other parts of the body at this stage.
DCIS is recognized as a precursor to invasive breast cancer. Around 20% of DCIS cases eventually transform into invasive cancer or recur after the primary growth is removed. However, researchers estimate that only about 3% of DCIS cases would progress into life-threatening cancers. The challenge is that doctors cannot yet reliably predict which cases will progress and which will remain harmless, and that uncertainty shapes most treatment decisions.
How Stage 0 Is Found
Most people with DCIS have no symptoms at all. The condition is almost always caught on a routine mammogram, where it typically appears as a cluster of microcalcifications: tiny white specks of calcium that show up on the image. These clusters can also be completely benign, so a mammogram finding alone doesn’t confirm DCIS. When microcalcifications look suspicious, a biopsy (removing a small sample of tissue with a needle) is the next step to determine whether abnormal cells are present.
The rise in mammographic screening over the past few decades is the main reason DCIS diagnoses have increased so dramatically. Between 17% and 34% of cancers detected by mammography turn out to be DCIS.
DCIS vs. LCIS
You may also come across the term lobular carcinoma in situ, or LCIS, which involves the breast’s milk-producing lobules rather than the ducts. Despite the similar name, LCIS is treated very differently. It’s considered a risk factor for future breast cancer rather than a direct precursor. Only about 7% to 12% of women with pure LCIS develop invasive disease, compared to roughly 30% for DCIS at 10 years. Most women with LCIS are offered increased monitoring rather than surgery or radiation.
Treatment After a Diagnosis
The 10-year survival rate for women diagnosed with DCIS is 98%, regardless of which treatment path they follow. That’s a reassuring number, but it also makes the treatment conversation more nuanced. The goal of treatment isn’t primarily survival; it’s reducing the chance that DCIS will return or develop into invasive cancer.
The most common approach is breast-conserving surgery (lumpectomy), which removes the area of DCIS along with a margin of healthy tissue. Some women opt for mastectomy, particularly if DCIS is widespread across the breast or appears in multiple areas. About 40% of DCIS patients at major cancer centers undergo mastectomy, though that rate varies by institution and patient preference.
Radiation After Lumpectomy
For women who have a lumpectomy, radiation to the whole breast significantly lowers the odds of recurrence. In a study following patients for 12 years, the recurrence rate was 2.8% for those who received radiation compared to 11.4% for those who did not. The rate of invasive recurrence specifically dropped from 5.8% to 1.5% with radiation. These numbers mean radiation cuts the relative risk of recurrence by roughly 75%, though the absolute risk is already low for many patients.
Hormone Therapy
If the DCIS cells test positive for hormone receptors, which means they are fueled by estrogen, hormone-blocking medication can further reduce the risk of future breast cancer. In a large clinical trial, women with hormone receptor-positive DCIS who took tamoxifen for five years had a 42% lower rate of developing any subsequent breast cancer compared to those who took a placebo. The benefit was strongest for preventing cancer in the opposite breast, where the risk was cut in half. For women whose DCIS is not hormone receptor-positive, tamoxifen showed no meaningful benefit.
It’s worth noting that neither radiation nor hormone therapy improves the overall survival rate for DCIS patients. Both treatments reduce the chance of recurrence, but the 98% 10-year survival holds with or without them. This is why the decision often comes down to personal comfort with risk and willingness to accept side effects.
Active Monitoring as an Option
Because so many DCIS cases never become dangerous, researchers have been studying whether some women can safely skip surgery altogether. The COMET trial, a major clinical study of 957 participants with low-risk DCIS (hormone receptor-positive, lower grade), compared active monitoring with standard surgical care. At two years, the rate of invasive cancer developing in the affected breast was 4.2% in the monitoring group and 5.9% in the surgery group, confirming that active monitoring was not inferior in the short term.
Active monitoring means regular mammograms and clinical exams, sometimes combined with hormone therapy, instead of immediate surgery. This approach is still being studied for longer-term outcomes, and it’s currently limited to specific low-risk profiles. But for women who fit the criteria, it represents a meaningful alternative to surgery for a condition that may never threaten their health.
What the Diagnosis Feels Like Emotionally
Hearing the word “cancer” in a diagnosis understandably causes alarm, and the language around DCIS is genuinely confusing. It is called cancer in staging systems, yet the National Cancer Institute describes it as “not cancer” in the traditional sense. Some researchers and advocates have pushed for renaming it entirely to reduce the anxiety and potential overtreatment that the cancer label can trigger. Regardless of terminology, the prognosis for stage 0 is excellent, and most women have time to carefully weigh their options before making a treatment decision.